Overview

Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Aura Biosciences